Peptide Graded

Pemvidutide

Is Pemvidutide safe?

Small phase 2 samples; no long-term data

BSome human evidenceIn clinical trialsas of 2026-10-27

Side effects in both trials were mostly in the gut, nausea and vomiting above all. This is true of every GLP-1-based drug. The sponsor reported that fixed dosing without step-up was tolerated. Few people stopped the drug for side effects. The glucagon part raises theoretical worries about blood sugar and heart rate. The published trials showed no sign of high blood sugar. But the samples are small, and they did not include people with poorly controlled diabetes. 23

Long-term safety is unknown. The longest controlled use published is 24 weeks in 212 patients. That cannot detect uncommon harms. No one has reported what happens to weight and liver fat when the drug is stopped. 2

Read the full Pemvidutide page

More on Pemvidutide

Citations

  1. StatPearls: glucagon-like peptide-1 receptor agonists ncbi.nlm.nih.gov
  2. 2025, Lancet: safety and efficacy of weekly pemvidutide versus placebo for MASH, 24-week results of the IMPACT phase 2b trial doi.org
  3. Browne 2025, JHEP Reports: safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease, randomized controlled trial doi.org
  4. ClinicalTrials.gov: NCT07795164, PERFORMA phase 3 trial of pemvidutide in MASH clinicaltrials.gov

Reference information only, not medical advice. Drawn from the Pemvidutide article, fact-checked against the cited sources. No dosing anywhere on this site.